FILTER
LATEST INTERVIEWS
Marcelo Schumacker
COUNTRY DIVISION MANAGER, ABB CHILE
ABB explains why Chile provides an excellent market for its mining technologies.
Sandro Tavonatti
CEO, SIGDO KOPPERS INGENIERÍA Y CONSTRUCCIÓN (SKIC)
Sigdo Koppers Ingeniería y Construcción (SKIC) explains how it operates with Chile’s largest mines.
Florencio Castro & Alexandra Almenara
VP – PERU & VP ENVIRONMENT AND SUSTAINABILITY – SOUTH AMERICA, AUSENCO
Ausenco in Peru relates how it is developing the capacity to provide an integral service of engineering, environmental and social services to any project at any stage of their life cycle.
Belisario Tijero
GENERAL MANAGER – PERU, MASTER DRILLING
Master Drilling updates GBR on current drilling trends in Peru.
John Patrick Oroho
EXECUTIVE VICE PRESIDENT & CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES LLC
Porzio Life Sciences LLC explains how it helps pharma companies with complex reporting requirements.
Brad Payne & Chris Blanton & Morgan Brandt
COO & VP AND GENERAL MANAGER & GLOBAL DIRECTOR, DIGITAL PRODUCTS, PCI PHARMA SERVICES
PCI Pharma Services relates its rapid expansion in both services and geography.
Johnson Lai
VP, CHEMICAL SPECIALTIES LIMITED (CSL)
CSL explains how it can help MNCs quickly grow their manufacturing footprint in Asia to tap into the fast-developing APAC and Middle Eastern markets with minimal capital investment.
Mark Berggren
CEO, METHANOL MARKET SERVICES ASIA (MMSA)
Methanol Market Services Asia explains its services as a methanol market advisory.
Hugo Salamanca
PRESIDENT, HIGHSERVICE CORP
HighService Corp in Chile explains its’ vision is to become a leading robotics company worldwide in the mining and heavy industry sectors.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
